Chronic Kidney Disease (CKD) Drugs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, India - Size and Forecast 2024-2028

Published: Nov 2023

Pages: 184

SKU: IRTNTR76853

Snapshot

Chronic Kidney Disease (CKD) Drugs Market 2024-2028

The global chronic kidney disease (CKD) drugs market size is estimated to grow by USD 3.81 billion at a CAGR of 4.77% between 2023 and 2028.

Growing awareness about the importance of the early detection and diagnosis of CKD is an important driver propelling the growth of the global CKD drugs market. Public health campaigns, medical education initiatives, and raised access to information related to the importance of treating chronic diseases, such as CKD, have collectively elevated awareness regarding the risk factors and symptoms associated with CKD. Furthermore, early detection is important in controlling CKD effectively, as interventions at the early stages can help slow down disease progression and mitigate difficulties. The focus on routine screenings, mainly for people with risk factors such as diabetes and hypertension, has become a focal point of healthcare strategies on CKD across the globe. Consequently, rising awareness about the significance of the early detection and diagnosis of CKD is anticipated to fuel the growth of the market during the forecast period.

Technavio has segmented the market into Drug Class, Route Of Administration, and Geography

The drug class segment includes erythropoietin stimulating agents, calcium channel blockers, phosphate binders, ace inhibitors, and others.
The route of administration segment includes oral, subcutaneous, and intravenous.
The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW).

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.

What will be the size of the Chronic Kidney Disease (CKD) Drugs Market During the Forecast Period?

To learn more about this report, Request Free Sample

Chronic Kidney Disease (CKD) Drugs Market Segmentation by Drug Class, Route Of Administration, and Geography Analysis

Drug Class Analysis

Erythropoietin stimulating agents

The market share growth by the erythropoietin stimulating agents segment will be significant during the forecast period. ESAs play an important role in the management of CKD by managing the issue of anemia, a typical complication associated with impaired kidney function. In CKD patients, the lowered ability of the kidneys to produce erythropoietin leads to anemia, contributing to fatigue and a reduced oxygen-carrying capacity in the blood. ESAs help relieve anemia by stimulating the bone marrow to produce more red blood cells, thereby improving hemoglobin levels and alleviating the symptoms related to anemia.

Get a glance at the market contribution of various segments Download PDF Sample

The erythropoietin stimulating agents segment was valued at USD 4.0 billion in 2018. Several pharmaceutical firms provide the ESA class of drugs as part of their product portfolios. In addition, ESAs include an important role in the therapeutic approach for managing anemia in CKD patients, improving their quality of life, and addressing a significant aspect of the disease. Consequently, the rising use of the ESA class of drugs, owing to their benefits in treating CKD-induced anemia, is expected to drive the growth of the chronic kidney disease drugs market during the forecast period.

Route Of Administration Analysis

Oral

The oral route of administration plays an important role in the delivery of medications for the management of CKD. The oral route of administration is a preferred and commonly used approach for CKD drugs, delivering comfort and ease of use for patients undergoing prolonged treatment for CKD. The oral route is particularly suitable for drugs that require systemic distribution and those aimed at addressing conditions or complications associated with CKD, such as hypertension, anemia, and mineral and bone disorders. In addition, the increasing consumption of oral medications for CKD is expected to drive the growth of the oral segment of the chronic kidney disease drugs market during the forecast period.

Subcutaneous

The subcutaneous route of administration is a vital method for giving medications for the management of CKD. Subcutaneous administration is often used for CKD drugs that require a steady and sustained release, therefore delivering a more prolonged therapeutic effect. Compared with oral medications, this allows the medication to enter the bloodstream more quickly; however, in the case of anemia, it might take a few weeks for the body to start making more red blood cells. Furthermore, Aranesp (darbepoetin alfa) and Procrit (epoetin alfa) are the two main injectable treatment options currently available for anemia in patients with CKD. Thus, such factors will fuel the growth of the subcutaneous segment of the market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 35% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The US and Canada accounted for the largest market shares in the region. The growth of the chronic kidney disease (CKD) drugs market in North America can be attributed to the high prevalence of CKD in the region, the existence of advanced healthcare infrastructure, and the strong presence of the leading chronic kidney disease drugs market players.

Furthermore, the key CKD drugs market players in the region continue to drive innovation in CKD therapeutics by leveraging their extensive R&D capabilities and ensuring a robust market presence and the availability of diverse treatment options for the growing population affected by CKD in North America, which thereby will continue to drive the growth of the regional chronic kidney disease (CKD) drugs market during the forecast period.

Buy Full Report Now

Key Chronic Kidney Disease (CKD) Drugs Market Players

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Abbott Laboratories: The company offers chronic kidney disease drugs such as bardoxolone methyl, which is the first medicine to demonstrate improvement in kidney function in patients.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Chronic Kidney Disease (CKD) Drugs Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.

Key Chronic Kidney Disease (CKD) Drugs Market Drivers

The rising prevalence of CKD is the key factor driving market growth. Chronic kidney disease (CKD) is one of the most typical non-communicable chronic diseases in the world today. The rising number of people diagnosed with diabetes is one of the major contributing causes to the rising prevalence of chronic kidney disease. Diabetes, hypertension, vascular disease, and glomerulonephritis are some of the major causes of CKD. In most underdeveloped and developing countries, glomerulonephritis and interstitial nephritis are the two major causes of CKD, owing to the high prevalence of infections.

In addition, CKD is also associated with an increased risk of cardiovascular disease, infections, diabetes, and cancer. Therefore, the rising prevalence of CKD worldwide is expected to increase the need for CKD drugs, which will subsequently raise the growth of the global CKD drugs market during the forecast period.

Significant Chronic Kidney Disease (CKD) Drugs Market Trends

Technological innovations in CKD treatment is the primary trend shaping market growth. Technological inventions are improving diagnostics, treatment modalities, and patient care. One significant innovation is the integration of digital health solutions, such as telehealth platforms and mobile applications, which facilitate remote patient monitoring and engagement. Such technologies allow real-time data collection, permitting healthcare providers to track the progression of CKD, dedication to medication among patients, and patient outcomes more effectively.

Furthermore, artificial intelligence (AI) and machine learning are being employed to analyze large datasets and identify patterns that can lead to better treatment decisions. AI applications can assist in predicting disease progression, optimizing the dosages of CKD drugs, and personalizing treatment plans based on individual patient characteristics. Therefore, technological inventions in CKD treatment are anticipated to fuel the growth of the global CKD drugs market during the forecast period.

Major Chronic Kidney Disease (CKD) Drugs Market Challenges

Growing competition from generic CKD drugs is a challenge that affects market growth. As most of the patents on original branded CKD medications part, generic versions that deliver more cost-effective alternatives to CKD patients enter the market. Significant examples include generic formulations of ACE inhibitors like enalapril and lisinopril, as well as generic versions of angiotensin receptor blockers (ARBs) such as losartan. While they are bioequivalent to their branded counterparts, these generic CKD drugs typically come at a lower cost, leading to increased market adoption.

Moreover, the availability of generic CKD drugs exercises a low pressure on the prices of other branded medications for CKD, thereby negatively affecting the revenue streams of the original manufacturers. The challenge lies in balancing the affordability delivered by generics with the need for constant innovation and the development of more advanced CKD treatments, which provide the sustained growth of market players in an increasingly competitive market landscape. Thus, such factors may impede the growth of the global CKD drugs market during the forecast period.

Buy Now Full Report

Key Chronic Kidney Disease (CKD) Drugs Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Chronic Kidney Disease (CKD) Drugs Market Customer Landscape

Segment Overview

The chronic kidney disease (CKD) drugs market report forecasts market growth by revenue at global, regional & country levels and analyzes the latest trends and growth opportunities from 2018 to 2028.

Drug Class Outlook
- Erythropoietin stimulating agents
- Calcium channel blockers
- Phosphate binders
- ACE inhibitors
- Others

Route Of Administration Outlook
- Oral
- Subcutaneous
- Intravenous

Region Outlook
- North America
  - The U.S.
  - Canada
- Europe
  - The U.K.
  - Germany
  - France
  - Rest of Europe
- Asia
  - China
  - India
- Rest of the World (ROW)
  - Argentina
  - Brazil
  - Australia

Chronic Kidney Disease (CKD) Drugs Market Scope
Report Coverage	Details
Page number	184
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 4.77%
Market Growth 2024-2028	USD 3.81 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	4.57
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 35%
Key countries	US, Germany, UK, China, and India
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	Abbott Laboratories, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Cara Therapeutics Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., FibroGen Inc., Horizon Therapeutics Plc, Johnson and Johnson, Kissei Pharmaceutical Co. Ltd., Novartis AG, OPKO Health Inc., Pfizer Inc., Pharmacosmos AS, Rockwell Medical Inc., Sanofi SA, Shield Therapeutics plc, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Xenetic Biosciences Inc., Zydus Lifesciences Ltd., Ardelyx Inc., and Aurinia Pharmaceuticals Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Chronic Kidney Disease (CKD) Drugs Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the chronic kidney disease (CKD) drugs market between 2024 and 2028
Precise estimation of the size of the chronic kidney disease (CKD) drugs market size and its contribution to the market in focus on the parent market
Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria
Companies landscape comparing criticality of inputs and factors of differentiation
Exclusive Matrix on companies' position and classification
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
A thorough analysis of the market’s competitive landscape and detailed information about companies
Comprehensive analysis of factors that will challenge the growth of chronic kidney disease (ckd) drugs market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Drug Class
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Route of Administration
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2023

3.4 Market outlook: Forecast for 2023-2028
- Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
- Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global chronic kidney disease (CKD) drugs market 2018 - 2022
- Exhibit 18: Historic Market Size – Data Table on global chronic kidney disease (ckd) drugs market 2018 - 2022 ($ billion)

4.2 Drug Class Segment Analysis 2018 - 2022
- Exhibit 19: Historic Market Size – Drug Class Segment 2018 - 2022 ($ billion)

4.3 Route of Administration Segment Analysis 2018 - 2022
- Exhibit 20: Historic Market Size – Route of Administration Segment 2018 - 2022 ($ billion)

4.4 Geography Segment Analysis 2018 - 2022
- Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)

4.5 Country Segment Analysis 2018 - 2022
- Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2023 and 2028

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Drug Class

6.1 Market segments
- Exhibit 30: Chart on Drug Class - Market share 2023-2028 (%)
- Exhibit 31: Data Table on Drug Class - Market share 2023-2028 (%)

6.2 Comparison by Drug Class
- Exhibit 32: Chart on Comparison by Drug Class
- Exhibit 33: Data Table on Comparison by Drug Class

6.3 Erythropoietin stimulating agents (ESAs) - Market size and forecast 2023-2028
- Exhibit 34: Chart on Erythropoietin stimulating agents (ESAs) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 35: Data Table on Erythropoietin stimulating agents (ESAs) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 36: Chart on Erythropoietin stimulating agents (ESAs) - Year-over-year growth 2023-2028 (%)
- Exhibit 37: Data Table on Erythropoietin stimulating agents (ESAs) - Year-over-year growth 2023-2028 (%)

6.4 Calcium channel blockers - Market size and forecast 2023-2028
- Exhibit 38: Chart on Calcium channel blockers - Market size and forecast 2023-2028 ($ billion)
- Exhibit 39: Data Table on Calcium channel blockers - Market size and forecast 2023-2028 ($ billion)
- Exhibit 40: Chart on Calcium channel blockers - Year-over-year growth 2023-2028 (%)
- Exhibit 41: Data Table on Calcium channel blockers - Year-over-year growth 2023-2028 (%)

6.5 Phosphate binders - Market size and forecast 2023-2028
- Exhibit 42: Chart on Phosphate binders - Market size and forecast 2023-2028 ($ billion)
- Exhibit 43: Data Table on Phosphate binders - Market size and forecast 2023-2028 ($ billion)
- Exhibit 44: Chart on Phosphate binders - Year-over-year growth 2023-2028 (%)
- Exhibit 45: Data Table on Phosphate binders - Year-over-year growth 2023-2028 (%)

6.6 ACE inhibitors - Market size and forecast 2023-2028
- Exhibit 46: Chart on ACE inhibitors - Market size and forecast 2023-2028 ($ billion)
- Exhibit 47: Data Table on ACE inhibitors - Market size and forecast 2023-2028 ($ billion)
- Exhibit 48: Chart on ACE inhibitors - Year-over-year growth 2023-2028 (%)
- Exhibit 49: Data Table on ACE inhibitors - Year-over-year growth 2023-2028 (%)

6.7 Others - Market size and forecast 2023-2028
- Exhibit 50: Chart on Others - Market size and forecast 2023-2028 ($ billion)
- Exhibit 51: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
- Exhibit 52: Chart on Others - Year-over-year growth 2023-2028 (%)
- Exhibit 53: Data Table on Others - Year-over-year growth 2023-2028 (%)

6.8 Market opportunity by Drug Class
- Exhibit 54: Market opportunity by Drug Class ($ billion)
- Exhibit 55: Data Table on Market opportunity by Drug Class ($ billion)

7 Market Segmentation by Route of Administration

7.1 Market segments
- Exhibit 56: Chart on Route of Administration - Market share 2023-2028 (%)
- Exhibit 57: Data Table on Route of Administration - Market share 2023-2028 (%)

7.2 Comparison by Route of Administration
- Exhibit 58: Chart on Comparison by Route of Administration
- Exhibit 59: Data Table on Comparison by Route of Administration

7.3 Oral - Market size and forecast 2023-2028
- Exhibit 60: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
- Exhibit 61: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
- Exhibit 62: Chart on Oral - Year-over-year growth 2023-2028 (%)
- Exhibit 63: Data Table on Oral - Year-over-year growth 2023-2028 (%)

7.4 Subcutaneous - Market size and forecast 2023-2028
- Exhibit 64: Chart on Subcutaneous - Market size and forecast 2023-2028 ($ billion)
- Exhibit 65: Data Table on Subcutaneous - Market size and forecast 2023-2028 ($ billion)
- Exhibit 66: Chart on Subcutaneous - Year-over-year growth 2023-2028 (%)
- Exhibit 67: Data Table on Subcutaneous - Year-over-year growth 2023-2028 (%)

7.5 Intravenous - Market size and forecast 2023-2028
- Exhibit 68: Chart on Intravenous - Market size and forecast 2023-2028 ($ billion)
- Exhibit 69: Data Table on Intravenous - Market size and forecast 2023-2028 ($ billion)
- Exhibit 70: Chart on Intravenous - Year-over-year growth 2023-2028 (%)
- Exhibit 71: Data Table on Intravenous - Year-over-year growth 2023-2028 (%)

7.6 Market opportunity by Route of Administration
- Exhibit 72: Market opportunity by Route of Administration ($ billion)
- Exhibit 73: Data Table on Market opportunity by Route of Administration ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 75: Chart on Market share by geography 2023-2028 (%)
- Exhibit 76: Data Table on Market share by geography 2023-2028 (%)

9.2 Geographic comparison
- Exhibit 77: Chart on Geographic comparison
- Exhibit 78: Data Table on Geographic comparison

9.3 North America - Market size and forecast 2023-2028
- Exhibit 79: Chart on North America - Market size and forecast 2023-2028 ($ billion)
- Exhibit 80: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
- Exhibit 81: Chart on North America - Year-over-year growth 2023-2028 (%)
- Exhibit 82: Data Table on North America - Year-over-year growth 2023-2028 (%)

9.4 Europe - Market size and forecast 2023-2028
- Exhibit 83: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
- Exhibit 84: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
- Exhibit 85: Chart on Europe - Year-over-year growth 2023-2028 (%)
- Exhibit 86: Data Table on Europe - Year-over-year growth 2023-2028 (%)

9.5 Asia - Market size and forecast 2023-2028
- Exhibit 87: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
- Exhibit 88: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
- Exhibit 89: Chart on Asia - Year-over-year growth 2023-2028 (%)
- Exhibit 90: Data Table on Asia - Year-over-year growth 2023-2028 (%)

9.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Exhibit 91: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 92: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
- Exhibit 93: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Exhibit 94: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)

9.7 US - Market size and forecast 2023-2028
- Exhibit 95: Chart on US - Market size and forecast 2023-2028 ($ billion)
- Exhibit 96: Data Table on US - Market size and forecast 2023-2028 ($ billion)
- Exhibit 97: Chart on US - Year-over-year growth 2023-2028 (%)
- Exhibit 98: Data Table on US - Year-over-year growth 2023-2028 (%)

9.8 China - Market size and forecast 2023-2028
- Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ billion)
- Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ billion)
- Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
- Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)

9.9 Germany - Market size and forecast 2023-2028
- Exhibit 103: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
- Exhibit 104: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
- Exhibit 105: Chart on Germany - Year-over-year growth 2023-2028 (%)
- Exhibit 106: Data Table on Germany - Year-over-year growth 2023-2028 (%)

9.10 UK - Market size and forecast 2023-2028
- Exhibit 107: Chart on UK - Market size and forecast 2023-2028 ($ billion)
- Exhibit 108: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
- Exhibit 109: Chart on UK - Year-over-year growth 2023-2028 (%)
- Exhibit 110: Data Table on UK - Year-over-year growth 2023-2028 (%)

9.11 India - Market size and forecast 2023-2028
- Exhibit 111: Chart on India - Market size and forecast 2023-2028 ($ billion)
- Exhibit 112: Data Table on India - Market size and forecast 2023-2028 ($ billion)
- Exhibit 113: Chart on India - Year-over-year growth 2023-2028 (%)
- Exhibit 114: Data Table on India - Year-over-year growth 2023-2028 (%)

9.12 Market opportunity by geography
- Exhibit 115: Market opportunity by geography ($ billion)
- Exhibit 116: Data Tables on Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 117: Impact of drivers and challenges in 2023 and 2028

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 118: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 119: Overview on factors of disruption

11.4 Industry risks
- Exhibit 120: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 121: Vendors covered

12.2 Market positioning of vendors
- Exhibit 122: Matrix on vendor position and classification

12.3 Abbott Laboratories
- Exhibit 123: Abbott Laboratories - Overview
- Exhibit 124: Abbott Laboratories - Business segments
- Exhibit 125: Abbott Laboratories - Key news
- Exhibit 126: Abbott Laboratories - Key offerings
- Exhibit 127: Abbott Laboratories - Segment focus

12.4 AbbVie Inc.
- Exhibit 128: AbbVie Inc. - Overview
- Exhibit 129: AbbVie Inc. - Product / Service
- Exhibit 130: AbbVie Inc. - Key news
- Exhibit 131: AbbVie Inc. - Key offerings

12.5 Amgen Inc.
- Exhibit 132: Amgen Inc. - Overview
- Exhibit 133: Amgen Inc. - Product / Service
- Exhibit 134: Amgen Inc. - Key offerings

12.6 AstraZeneca Plc
- Exhibit 135: AstraZeneca Plc - Overview
- Exhibit 136: AstraZeneca Plc - Product / Service
- Exhibit 137: AstraZeneca Plc - Key news
- Exhibit 138: AstraZeneca Plc - Key offerings

12.7 Bayer AG
- Exhibit 139: Bayer AG - Overview
- Exhibit 140: Bayer AG - Business segments
- Exhibit 141: Bayer AG - Key news
- Exhibit 142: Bayer AG - Key offerings
- Exhibit 143: Bayer AG - Segment focus

12.8 Biogen Inc.
- Exhibit 144: Biogen Inc. - Overview
- Exhibit 145: Biogen Inc. - Product / Service
- Exhibit 146: Biogen Inc. - Key offerings

12.9 Boehringer Ingelheim International GmbH
- Exhibit 147: Boehringer Ingelheim International GmbH - Overview
- Exhibit 148: Boehringer Ingelheim International GmbH - Business segments
- Exhibit 149: Boehringer Ingelheim International GmbH - Key news
- Exhibit 150: Boehringer Ingelheim International GmbH - Key offerings
- Exhibit 151: Boehringer Ingelheim International GmbH - Segment focus

12.10 Eli Lilly and Co.
- Exhibit 152: Eli Lilly and Co. - Overview
- Exhibit 153: Eli Lilly and Co. - Product / Service
- Exhibit 154: Eli Lilly and Co. - Key news
- Exhibit 155: Eli Lilly and Co. - Key offerings

12.11 F. Hoffmann La Roche Ltd.
- Exhibit 156: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 157: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 158: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 159: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 160: F. Hoffmann La Roche Ltd. - Segment focus

12.12 Horizon Therapeutics Plc
- Exhibit 161: Horizon Therapeutics Plc - Overview
- Exhibit 162: Horizon Therapeutics Plc - Business segments
- Exhibit 163: Horizon Therapeutics Plc - Key news
- Exhibit 164: Horizon Therapeutics Plc - Key offerings
- Exhibit 165: Horizon Therapeutics Plc - Segment focus

12.13 Johnson and Johnson
- Exhibit 166: Johnson and Johnson - Overview
- Exhibit 167: Johnson and Johnson - Business segments
- Exhibit 168: Johnson and Johnson - Key news
- Exhibit 169: Johnson and Johnson - Key offerings
- Exhibit 170: Johnson and Johnson - Segment focus

12.14 Novartis AG
- Exhibit 171: Novartis AG - Overview
- Exhibit 172: Novartis AG - Business segments
- Exhibit 173: Novartis AG - Key offerings
- Exhibit 174: Novartis AG - Segment focus

12.15 OPKO Health Inc.
- Exhibit 175: OPKO Health Inc. - Overview
- Exhibit 176: OPKO Health Inc. - Business segments
- Exhibit 177: OPKO Health Inc. - Key offerings
- Exhibit 178: OPKO Health Inc. - Segment focus

12.16 Pfizer Inc.
- Exhibit 179: Pfizer Inc. - Overview
- Exhibit 180: Pfizer Inc. - Product / Service
- Exhibit 181: Pfizer Inc. - Key news
- Exhibit 182: Pfizer Inc. - Key offerings

12.17 Sanofi SA
- Exhibit 183: Sanofi SA - Overview
- Exhibit 184: Sanofi SA - Business segments
- Exhibit 185: Sanofi SA - Key news
- Exhibit 186: Sanofi SA - Key offerings
- Exhibit 187: Sanofi SA - Segment focus

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 188: Inclusions checklist
- Exhibit 189: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 190: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 191: Research methodology
- Exhibit 192: Validation techniques employed for market sizing
- Exhibit 193: Information sources

13.5 List of abbreviations
- Exhibit 194: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

chronic kidney disease (ckd) drugs market market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis